As long as cannabis remains federally illegal and licensing remains the responsibility of states, each state may continue to act based on their own estimation of the trade-oﬀs involved, which can carry negative externalities for other.
The move would enable the Company to synthesize, process and distribute pharmaceutical grade 3,4-Methylenedioxymethamphetamine (“MDMA”), among other substances, at its Princeton, British Columbia facility.
Susanne Caspar, CEO of Linnea, a Switzerland-based CBD company, tells Analytical Cannabis what comes next after the EFSA's recent decision.
The lab is now certified to test hemp samples for 102 pesticides – the most expansive hemp pesticide list in the US.
A new review published in the Journal of Pain and Symptom Management has concluded that while positive treatment effects have been reported for some medical cannabis formulations, there are significant quality problems with current evidence.
New research published in the journal Frontiers in Pharmacology has found that the mystical experiences induced by psilocybin are closely linked to long-lasting positive psychological effects in healthy individuals.
A second paper is scheduled to be published later in 2022 which will examine the effect of medical cannabis treatment on these patients at the three- and six-month follow-up appointments.
Before the announcement, the European agency had been processing 19 applications for CBD products, all of which are now in limbo.